[This review was originally posted at the Nieman Journalism Lab on Nov. 8, 2013.] Will Twitter follow Facebook’s path?: Twitter […]
[This review was originally published at the Nieman Journalism Lab on Oct. 4, 2013.] False equivalence and the shutdown: The […]
[This review was originally posted at the Nieman Journalism Lab on Sept. 13, 2013.] Encryption, surveillance, and academic freedom: There were a […]
[This review was originally posted at the Nieman Journalism Lab Order Synthroid, on June 1, 2012.]
Debating the meaning of Facebook’s IPO flop: Facebook’s fall following its initial public offering two weeks ago continued this week, with shares dropping under $30 (they were initially offered at $38). Several other social media-based companies have seen their stock tank, too, prompting Forbes’ Dee Gill to wonder if Facebook’s IPO has been a reminder that “even a wildly popular product won’t save a company that can’t make money.”
David Strom of ReadWriteWeb did point out, though, that stock prices soon after tech IPOs haven’t been a very reliable indicator of companies’ prospects for long-term success. The New York Times’ Joe Nocera made a similar point, arguing that Facebook’s IPO flop was fueled by get-rich-quick investors and that long-term investors should be undeterred, Synthroid treatment.
At PandoDaily, Farhad Manjoo made the case that Facebook’s IPO was a valuable corrective to a dangerously overhyped tech market: “Facebook’s IPO proves that there isn’t an endless supply of bigger suckers. And because bigger suckers are the primary ingredients in bubbles, it now seems likely that the new tech bubble—if there ever was one—is dead, dead, dead.” And The Atlantic’s Alexis Madrigal made a pretty thorough defense of Facebook’s value as a company, Synthroid forum, reminding us that it has a still-growing near-monopoly and tremendous potential for making money from its millions of users.
There was still plenty of criticism of Facebook floating around this week, though, Order Synthroid. The New York Times’ Ross Douthat saw Facebook as a sign of the lack of financial progress brought by the Internet economy, and Facebook’s advertising shortcomings continued to be a point of discussion. Ad Age reported that GM pulled its advertising from Facebook in part because Facebook balked at its proposal to run full-page ads, which, according to media consultant Terry Heaton, illustrated the difference between Madison Avenue’s philosophy of bending the masses to their will and Facebook’s gentler approach. The Huffington Post’s Bianca Bosker also looked at the tension Facebook is facing between its advertisers and users, Synthroid maximum dosage.
Here at the Lab, Dan Kennedy extended the ad problem to journalists, proposing a few ideas for adapting to an online world in which the value of ads continues to shrink. Order Synthroid, Also on the news front, Buzzfeed’s John Herrman wrote about how coverage on Twitter of the Facebook IPO indicates that Twitter is well ahead of Facebook in covering and developing breaking stories.
Another major note on Facebook to keep an eye on: The New York Timesreported that the company is trying again to build a smartphone to release later this year. It’s had several false starts in this area before, but is moving “deeper into the process” this time. Is Synthroid addictive, Facebook was also reported this week to be buying the facial recognition company Face.com.
The impact of New Orleans’ move away from print: As we moved into the second week of discussion of the New Orleans Times-Picayune’s cutback from daily newspaper production, the conversation began to shift from New Orleans in particular to the future of the newspaper industry as a whole. Poynter’s Steve Myers looked at a couple of the immediate issues — concerns over whether Advance Publications’ other papers (such as the Cleveland Plain Dealer) might make similar cuts, and whether New Orleans readers are likely to follow their paper online, Order Synthroid.
The New York Times’ David Carr, who broke the story, wrote a kind of elegy for the paper, concluding that while the cutback may make some financial sense, it’s a great loss for a historically corrupt city. “The constancy of a paper, ordering Synthroid online,” he wrote, “is a reminder to a city that someone is out there watching.” At the Huffington Post, Harry Shearer thought Carr wasn’t harsh enough in his assessment of Advance’s plans, arguing that breaking readers’ daily newspaper habits is foolish, not economical. Shearer, Synthroid wiki, Myers, and Iowa journalist Dave Schwartz all pointed out that New Orleans has particularly low Internet penetration rates (not to mention high newspaper penetration rates), with Schwartz calling those without web access “casualties in a revolution.”
Mathew Ingram of GigaOM and CUNY prof Jeff Jarvis, on the other hand, both argued that we need to get past our fixation with print journalism, using it when it’s profitable but feeling free to drop it when it’s not. “We have to make print beside the point,” Jarvis wrote, Synthroid without prescription. Will Bunch of the Philadelphia Daily News, meanwhile, proposed some ideas at Poynter for resolving the journalism crisis in New Orleans, focusing on philanthropic efforts to improve Internet access, hyperlocal journalism, and accountability journalism. Al Jazeera discussed the future of the newspaper industry Order Synthroid, in light of New Orleans’ move away from daily with a few luminaries as well. Synthroid dangers,
While Postmedia CEO Paul Godfrey complained in an interview with the Globe & Mail that its ad revenue was being stolen by foreign digital companies (read: Google, AOL, etc.), GigaOM’s Mathew Ingram said the problems for Postmedia and other newspapers run much deeper than cuts and paywalls. Synthroid street price, Crain’s Chicago Business also reported that the Chicago Tribune is considering a paywall potentially focusing on niche coverage, and Poynter’s Steve Myers pointed out that the major newspaper companies that aren’t charging for news are quickly becoming the outliers.
The paywall debate got a shot in the arm this week in the aftermath of the Times-Picayune’s cuts, when The Wire creator and former newspaper reporter David Simon asserted at the Columbia Journalism Review that “the whole industry will continue to collapse until everyone swallows hard and goes behind a paywall.”The short post spurred a feisty comment thread as well as several varying responses, Order Synthroid. A post at the news startup Circa made a distinction between charging for content (OK) and information (much more difficult to do), and Will Bunch made his aforementioned philanthropically driven proposals for New Orleans as a middle way between paywall advocates and detractors.
In addition, former newspaper editor John L. Robinson argued that if young people won’t even pay much for Facebook, they sure won’t pay for a newspaper — and that should worry newspaper publishers, Synthroid class. Here at the Lab, Ken Doctor added some practical approaches to the discussion, looking at the effectiveness of different newspapers’ plans to shift from advertiser revenue toward reader revenue.
Mathew Ingram of GigaOM echoed the idea, and meanwhile, Technically Philly’s Sean Blanda and blogger Dave Winer both wrote on rethinking the elements of an article — Blanda proposed thinking of the basic unit of journalism as the fact rather than the article, and Winer said we need to do better than Wikipedia when it comes to background information and explainers, Order Synthroid.
— WikiLeaks’ Julian Assange lost his appeal to the British Supreme Court against extradition to Sweden on accusations of a pair of 2010 sexual abuse cases. No prescription Synthroid online, He has two weeks to appeal one of the ruling’s points, but it looks as though he’s headed to Sweden to stand trial. Here’s The Guardian’s and The New York Times’ coverage, and Micah Sifry’s examination of the state of online whistleblowing as WikiLeaks struggles.
— A couple of ebook notes: Amazon settled its dispute Order Synthroid, with a publisher that pulled its books from the site earlier this year, and meanwhile, two other publishers filed responses to the Department of Justice’s antitrust suit on ebook pricing, and Apple filed its response to a parallel class-action suit.
— Web designer Oliver Reichenstein ripped the ubiquitous “Share” buttons all over news and other sites, while the Lab’s Joshua Benton provided some initial data showing they may be quite helpful for news orgs to prompt sharing of their content on Twitter.
— Cornell prof Tarleton Gillespie wrote an interesting post exploring whether we can trust Twitter’s Trending Topics algorithm, and GigaOM’s Mathew Ingram said it’s not necessarily Twitter’s job to broaden our worldview, Synthroid dose, but instead our own responsibility.
— Finally, it’s not shameless self-promotion if it’s actually really good: The Lab ran several fascinating pieces this week that are worth a look — Justin Ellis’ talk with Guardian editor Alan Rusbridger, some cool ideas for improving news from MIT Media Lab students courtesy of Andrew Phelps, and the AP’s Jonathan Stray’s smart column on broadening our concept of what journalists do. Enjoy.
Similar posts: Tramadol Cost. Glucophage Over The Counter. Diflucan Dosage. Bactrim price. Tramadol without a prescription. Tramadol overnight.
Trackbacks from: Order Synthroid. Order Synthroid. Order Synthroid. Buy Synthroid online cod. Synthroid pharmacy. Is Synthroid safe.
[This review was originally posted at the Nieman Journalism Lab Cephalexin Dosage, on May 25, 2012.]
Facebook’s quick fall: A week ago, Facebook had just launched the largest, most buzzworthy initial public offering in years. And now, that IPO has already brought them a potentially massive lawsuit and a federal investigation. Aside from the whole “pocketing millions upon millions of dollars” thing, it’s been a brutal week for Facebook execs. Here’s what happened.
Facebook dominated the conversation online last week (GigaOM has a good roundup from last Friday’s IPO), and a lot of that wasn’t positive, kjøpe Cephalexin på nett, köpa Cephalexin online. As data from Pew’s Project for Excellence in Journalism showed, much of the chatter online, particularly on Twitter, was about Facebook as an overhyped (and overvalued) stock, Cephalexin Dosage. Those online observers may have been more right than they knew: As reports from Reuters, Business Insider (two posts), and The Wall Street Journaldetailed, Facebook was allegedly telling top investors they had overestimated their projected financial figures, all while publicly talking up their earning potential and even expanding their stock offering to the rest of us. The result, My Cephalexin experience, so far, has been a U.S. Securities and Exchange Commission investigation and a (potentially class-action) lawsuit from investors.
There were a number of good analyses of what went wrong — at The Guardian, Heidi Moore laid out the list of sins involved and concluded, “Facebook didn’t know how to work its own privacy settings for investors. It couldn’t figure out, essentially, who should know what.” Reuters’ Felix Salmon was more specific with his list of incompetents, Cephalexin for sale, declaring that the only winners in this game were the ones who didn’t play at all. The Big Picture’s Barry Ritholtz also ripped apart the debacle Cephalexin Dosage, .
The whole scandal still leaves open the question of what Facebook should, in fact, be valued at. At Technology Review, Michael Wolff was most provocative with his assessment, Cephalexin without a prescription, arguing that Facebook is just another business inextricably reliant on a fatally flawed online advertising model: “The crash will come. And Facebook—that putative transformer of worlds, which is, in reality, only an ad-driven site—will fall with everybody else,” he wrote. Harvard’s Doc Searls echoed Wolff’s thoughts about the brokenness of Facebook’s (and the web’s) ad model, and media consultant Terry Heaton countered that the broken industry isn’t the ad-supported web, Cephalexin reviews, but Madison Avenue’s insistence on the status quo on that web.
Others looked more closely at the future of Facebook’s services and of the social web more generally, Cephalexin Dosage. The Atlantic’s Alexis Madrigal wondered whether Facebook’s users would keep sharing and what would become of its native and mobile users, and ReadWriteWeb’s Dan Frommer examined the company’s four biggest risks (there’s mobile and advertising again!). There were other problems spotted: All Things D’s Peter Kafka looked at the continued decline of Facebook’s Social Reader apps, and The New York Times’ Nick Bilton contrasted Facebook and Twitter’s approaches to privacy. Tech blogger Dave Winer insisted that we can do better than Facebook, What is Cephalexin, while Slate’s Farhad Manjoo contended that Facebook has improved Silicon Valley.
The end of an era for New Orleans news: The American newspaper industry absorbed another big blow this week when the New Orleans Times-Picayune announced that it would drop back from daily publication to just three days a week, a change accompanied by the creation of a new corporate entity to run the paper and heavy layoffs — possibly a third of the newsroom. Cephalexin Dosage, The change will leave New Orleans as the largest city in the U.S. without a daily newspaper.
The news was broken by The New York Times’ David Carr, and according to the New Orleans alt-weekly Gambit, Times-Picayune employees learned of the paper’s fate through his report. (They later got this memo from the paper’s publisher.) All this came despite the fact that, Cephalexin schedule, as Jim Romenesko reported, the paper remains profitable. For some of the background on the paper — which is owned by Advance Publications, a division of the Newhouse publishing empire — see this post at the Columbia Journalism Review. (Advance also announced they’d be doing the same thing with three of its Alabama papers, led by the Birmingham News.)
Media analyst Ken Doctor has an extremely useful analysis of what exactly Advance/Newhouse is trying to accomplish with this move, and what perils it faces, Cephalexin Dosage. Doctor called the paper’s transition to digital a “forced march” because the paper simply isn’t ready for a digital transformation, particularly in terms of digital circulation. Purchase Cephalexin online, Others were similarly skeptical: The immediate comparison was to Advance’s 2009 transition of the daily Ann Arbor News to AnnArbor.com, and Forbes’ Micheline Maynard gave a bleak picture of what’s left of that news organization and the hole it’s left in the community.
Forbes’ John McQuaid, a former Times-Picayune reporter, described the way Advance’s web strategy has been “only lightly tethered to newsgathering,” and concluded that “with Advance, news has always been an adjunct to its vanilla branded sites, not something that is driving the internal business conversation, Cephalexin samples, and it shows.” And former Wall Street Journal writer (and Times-Picayune intern) Jason Fry said he doesn’t see any reason for optimism that Advance will get the web right in this case.
Free Press’ Josh Stearns noted that while the future-of-news world has been optimistically focused on experiments to sustain quality journalism in certain hubs like San Francisco, Chicago, and New York, they need to pay closer attention to mid-sized cities like New Orleans, where the infrastructure simply isn’t there to pick up the journalism being cut at major traditional news organizations.
What’s behind Buffett’s newspaper buy?: I briefly mentioned Warren Buffett’s purchase Cephalexin Dosage, late last week of 63 newspapers from Media General in last week’s review, but some smart commentary has come out about the deal since then (along with a few other pieces I missed at the time), so it’s worth touching on again. Cephalexin long term, Media analyst Ken Doctor did a sharp rundown of the deal, pointing out that the upside of Media General’s broadcast properties and the real estate involved with the newspapers Buffett’s buying should help buffer him from the inherent danger of buying a set of newspapers. Reuters’ Jack Shafer pointed out several of Buffett’s past bearish statements about newspapers, but said he’s most likely buying because he sees an undervalued asset, not for any sentimental reason.
The Columbia Journalism Review’s Justin Peters and The Washington Post’s Erik Wemple both explained why these papers might be surprisingly valuable for Buffett: While major metro dailies have taken a beating, smaller community newspapers in rural areas have weathered the digital storm fairly well so far, in part because of their monopoly on local news and the slower rates of broadband adoption there, online buy Cephalexin without a prescription.
Former journalism professor Philip Meyer made a similar point, arguing that Buffett is the type of buyer who’s happy with the new normal of lower profit margins for newspapers: “It looks like he is betting that the slide in newspaper earning power has leveled out. The Internet has done all the damage it can, and papers still make money.” PaidContent’s Jeff John Roberts looked at the economic sense Buffett’s paywall plan makes, while media consultant Dan Conover said he should be open to other non-paywall-based models, Cephalexin Dosage. Poynter’s Andrew Beaujon, meanwhile, said we may be ignoring another big reason for news org purchases like Buffett’s — they’re a platform for personal philosophies of how journalism should be done. Buffett did tell his new papers’ publishers that he would be hands-off with them, Cephalexin dosage, and that he expected to buy more small and mid-sized papers.
The bill, which was supposedly meant as a weapon against cyber-bullying and attacks against “local businesses and elected officials,” was predictably (and rightly) met with derision from scholars and those on the web. Columbia’s Tim Wu told The Guardian the bill was “an obvious first amendment violation, Cephalexin blogs,” and the bill was also ripped at sites like Techdirt and Animal. BetaBeat reported that some of the lawmakers involved with the bill were surprised by the blowback about it, while The Atlantic brought out a dissenting opinion, with a point/counterpoint on the value of anonymous online discourse.
— The Wall Street Journal reported on some of the ongoing struggles with AOL’s hyperlocal journalism project, Patch, Comprar en línea Cephalexin, comprar Cephalexin baratos, breaking the news that 20 Patch employees were being laid off and that one of AOL’s major investors is trying to get Patch killed, sold, or put into a joint venture. Jeff Bercovici of Forbes said it’s going to take a lot more cost-cutting or revenue-raising to get Patch to profitability by next year, and The Washington Post’s Erik Wemple said hyperlocal journalism’s business model doesn’t have room for executives in suits, Cephalexin Dosage.
— The New York Times’ public editor, Arthur Brisbane, will leave his position in September after two years, declining an optional third year. The Washington Post’s Erik Wemple, Cephalexin from canadian pharmacy, who broke the story, took the opportunity to criticize his most recent column, and Poynter’s Craig Silverman proposed five qualifications for the next public editor of the Times. Poynter also held a chat about the role of ombudsmen with Washington Post ombudsman Patrick Pexton and Reuters’ Jack Shafer.
— This week in Murdoch was a relatively quiet one. Cephalexin Dosage, News Corp. was reported to be considering spinning off its British newspapers — the Sun, the Times, and the Sunday Times — in order to preserve the rest of its media empire, something Murdoch denied but the Columbia Journalism Review’s Emily Bell saw as quite sensible. Here at the Lab, Ken Doctor examined what a trust for those papers might look like.
— A couple of interesting pieces of survey data discussed this week: The study that drew most of the headlines was one that looked at the political knowledge of audiences for various news outlets, finding NPR’s listeners to be the most informed and Fox News’ viewers to be the least informed. Another study found that about half of media professionals abandon websites when they hit a paywall.
— Finally, a couple of cool pieces on data journalism — Simon Rogers of The Guardian urged us to take on the punk “anyone can do it” mindset toward data journalism, and Alex Howard of O’Reilly Radar talked with former Guardian digital editor Emily Bell about her efforts to put data journalism into action with students at Columbia University.
Similar posts: Synthroid Dosage. Cipro For Sale. Cipro Dosage. Cheap Zoloft. Generic Bactrim. Real brand Cipro online.
Trackbacks from: Cephalexin Dosage. Cephalexin Dosage. Cephalexin Dosage. Cephalexin from canada. Cephalexin wiki. No prescription Cephalexin online.